Effect of IVIG administration on complement activation and HLA antibody levels
暂无分享,去创建一个
H. Meier‐Kriesche | G. Burke | P. Ruiz | G. Guerra | J. Scornik | Takafumi Machimoto | J. Colona | F. Fricker
[1] D. Nochy,et al. Comparison of Combination Plasmapheresis/IVIg/Anti‐CD20 Versus High‐Dose IVIg in the Treatment of Antibody‐Mediated Rejection , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[2] S. Jordan,et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. , 2008, The New England journal of medicine.
[3] Y. Yamaguchi,et al. Usefulness of splenectomy for chronic active antibody‐mediated rejection after renal transplantation , 2008, Transplant international : official journal of the European Society for Organ Transplantation.
[4] S. Jordan,et al. Intravenous Gammaglobulin (IVIG): A Novel Approach to Improve Transplant Rates and Outcomes in Highly HLA‐Sensitized Patients , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[5] M. Stegall,et al. A Comparison of Plasmapheresis Versus High‐Dose IVIG Desensitization in Renal Allograft Recipients with High Levels of Donor Specific Alloantibody , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[6] J. Watanabe,et al. IVIG and HLA Antibodies. Evidence for Inhibition of Complement Activation but Not for Anti‐Idiotypic Activity , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[7] G. Opelz,et al. A Positive Crossmatch and Treatment with IvIg , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[8] P. Corris,et al. Functional Status and Quality of Life in Patients Surviving 10 years After Lung Transplantation , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[9] D. Stablein,et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. , 2004, Journal of the American Society of Nephrology : JASN.
[10] H. Marquart,et al. CR2‐mediated activation of the complement alternative pathway results in formation of membrane attack complexes on human B lymphocytes , 2001, Immunology.
[11] S. Kaveri,et al. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. , 2001, The New England journal of medicine.
[12] E. Kremmer,et al. Regulation of the B cell response to T-dependent antigens by classical pathway complement. , 1996, Journal of immunology.
[13] Christopher C. Goodnow,et al. C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity , 1996, Science.
[14] P. Kirshbom,et al. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. , 1989, The Journal of clinical investigation.
[15] M. Frank,et al. The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. , 1992, Clinical immunology and immunopathology.